These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 18775103

  • 1. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
    Mel JR, Salar A, Rodríguez CA, Alegre A, González A, Cassinello J, Montesinos J, Gasquet JA, Sánchez J, Saigí E, AMG-DAR-2002-01 Study Group.
    Curr Med Res Opin; 2008 Oct; 24(10):2931-42. PubMed ID: 18775103
    [Abstract] [Full Text] [Related]

  • 2. Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy.
    Esquerdo G, Doménech M, López P, Pedro C, Villadiego K, Constenla M, Sánchez-Rovira P, Gasquet JA, Rodríguez CA, AVANT study group.
    Tumori; 2014 Oct; 100(2):225-31. PubMed ID: 24852870
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level.
    Esquerdo G, Llorca C, Cervera JM, Orts D, Juárez A, Carrato A.
    Clin Transl Oncol; 2011 May; 13(5):341-7. PubMed ID: 21596663
    [Abstract] [Full Text] [Related]

  • 4. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
    Canon JL, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K.
    Med Oncol; 2012 Sep; 29(3):2291-9. PubMed ID: 22081263
    [Abstract] [Full Text] [Related]

  • 5. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
    Roger SD, Kolmakova E, Fung M, Malecki R, Vinhas J, Dellanna F, Thomas M, Manamley N, Ferenczi S.
    Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
    [Abstract] [Full Text] [Related]

  • 6. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
    Boccia R, Lillie T, Tomita D, Balducci L.
    Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
    Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloëguen C, Beyer U, STRIATA Study Investigators.
    Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
    [Abstract] [Full Text] [Related]

  • 13. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C.
    J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
    [Abstract] [Full Text] [Related]

  • 14. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study.
    Aerts JG, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B, Van Belle S.
    Curr Med Res Opin; 2012 Jul; 28(7):1089-99. PubMed ID: 22642866
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
    Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, Inamoto A, Lillie T.
    BMC Cancer; 2010 Oct 25; 10():581. PubMed ID: 20973982
    [Abstract] [Full Text] [Related]

  • 18. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
    Henry DH.
    Drugs; 2007 Oct 25; 67(2):175-94. PubMed ID: 17284083
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies.
    Hedenus M, Hansen S, Taylor K, Arthur C, Emmerich B, Dewey C, Watson D, Rossi G, Osterborg A, Darbepoetin alfa 990114 Study Group.
    Br J Haematol; 2002 Oct 25; 119(1):79-86. PubMed ID: 12358906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.